Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Neurology
2023 Nov 07;10119:842-852. doi: 10.1212/WNL.0000000000207757.
Show Gene links
Show Anatomy links
Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
Ramanan VK
,
Armstrong MJ
,
Choudhury P
,
Coerver KA
,
Hamilton RH
,
Klein BC
,
Wolk DA
,
Wessels SR
,
Jones LK
,
AAN Quality Committee
.
Abstract
With recent data demonstrating that lecanemab treatment can slow cognitive and functional decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug and potentially other monoclonal antibody infusions targeting β-amyloid protein will imminently be realistic options for some patients with AD. Given that these new antiamyloid monoclonal antibodies (mAbs) are associated with nontrivial risks and burdens of treatment that are radically different from current mainstays of AD management, effectively and equitably translating their use to real-world clinical care will require systematic and practice-specific modifications to existing workflows and infrastructure. In this Emerging Issues in Neurology article, we provide practical guidance for a wide audience of neurology clinicians on logistic adaptations and decision making around emerging antiamyloid mAbs. Specifically, we briefly summarize the rationale and available evidence supporting antiamyloid mAb use in AD to facilitate appropriate communication with patients and care partners on potential benefits. We also discuss pragmatic approaches to optimizing patient selection and treatment monitoring, with a particular focus on the value of incorporating shared decision making and multidisciplinary collaboration. In addition, we review some of the recognized limitations of current knowledge and highlight areas of future evolution to guide the development of sustainable and flexible models for treatment and follow-up. As the field enters a new era with disease-modifying treatment options for AD, it will be critical for neurology practices to prepare and continually innovate to ensure optimal outcomes for patients.
Budd Haeberlein,
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
2022, Pubmed
Budd Haeberlein,
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
2022,
Pubmed
Choudhury,
APOE Allele Testing and Alzheimer Disease-Reply.
2021,
Pubmed
Cogswell,
Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.
2022,
Pubmed
Cummings,
Lecanemab: Appropriate Use Recommendations.
2023,
Pubmed
Cummings,
Aducanumab: Appropriate Use Recommendations Update.
2022,
Pubmed
Day,
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.
2022,
Pubmed
Galvin,
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management.
2020,
Pubmed
Graff-Radford,
New insights into atypical Alzheimer's disease in the era of biomarkers.
2021,
Pubmed
Graff-Radford,
Cerebrospinal fluid dynamics and discordant amyloid biomarkers.
2022,
Pubmed
Greenberg,
Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.
2020,
Pubmed
Hansson,
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.
2018,
Pubmed
Hansson,
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
2022,
Pubmed
Hurd,
Monetary costs of dementia in the United States.
2013,
Pubmed
Jack,
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
2018,
Pubmed
Jack,
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
2013,
Pubmed
Jack,
Brain β-amyloid load approaches a plateau.
2013,
Pubmed
Karran,
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.
2022,
Pubmed
Knopman,
Alzheimer disease.
2021,
Pubmed
Knopman,
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
2021,
Pubmed
Knopman,
Mild cognitive impairment and mild dementia: a clinical perspective.
2014,
Pubmed
Lin,
Geographic Variation in Neurologist Density and Neurologic Care in the United States.
2021,
Pubmed
Mayeda,
Inequalities in dementia incidence between six racial and ethnic groups over 14 years.
2016,
Pubmed
Mehta,
Systematic review of dementia prevalence and incidence in United States race/ethnic populations.
2017,
Pubmed
Mintun,
Donanemab in Early Alzheimer's Disease.
2021,
Pubmed
Morris,
The Clinical Dementia Rating (CDR): current version and scoring rules.
1993,
Pubmed
Panza,
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.
2019,
Pubmed
Petersen,
Expectations and clinical meaningfulness of randomized controlled trials.
2023,
Pubmed
Rabinovici,
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
2019,
Pubmed
Rafii,
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
2023,
Pubmed
Rajan,
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
2021,
Pubmed
Raman,
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.
2022,
Pubmed
Reish,
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
2023,
Pubmed
Robinson,
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
2018,
Pubmed
Sabbagh,
Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
2023,
Pubmed
Shcherbinin,
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
2022,
Pubmed
Swanson,
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
2021,
Pubmed
Söderberg,
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
2023,
Pubmed
Tanzi,
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.
2005,
Pubmed
Therriault,
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment.
2021,
Pubmed
Tsoy,
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California.
2021,
Pubmed
Vimalananda,
Electronic consultations (e-consults) to improve access to specialty care: a systematic review and narrative synthesis.
2015,
Pubmed
Wolk,
A Step Forward in the Fight Against Dementia-Are We There Yet?
2023,
Pubmed
van Dyck,
Lecanemab in Early Alzheimer's Disease.
2023,
Pubmed
